Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.41 |
| ▸ | ADK | P55263 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26534106 | 0.91 | NT5E (0.43) | NT5E | |
| SCHEMBL24686959 | 0.86 | ADK (0.51) | SMN1; SMN2LMNAALDH1A1ADORA1ADK | |
| SCHEMBL26534105 | 0.78 | NT5E (0.36) | NT5ELMNA | |
| SCHEMBL6671150 | 0.76 | SMN1; SMN2 (0.49) | NT5ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL6421558 | 0.76 | ADORA1 (0.50) | SMN1; SMN2LMNAALDH1A1ADORA1ADK | |
| SCHEMBL24687189 | 0.76 | ADORA1 (0.50) | SMN1; SMN2LMNAALDH1A1ADORA1ADK | |
| SCHEMBL6674410 | 0.75 | SMN1; SMN2 (0.54) | NT5ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL22704891 | 0.75 | SMN1; SMN2 (0.54) | NT5ESMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL23023836 | 0.72 | ADK (0.72) | SMN1; SMN2LMNAALDH1A1ADKADORA3 | |
| SCHEMBL24687181 | 0.72 | ADK (0.72) | SMN1; SMN2LMNAALDH1A1ADKADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | NT5E 191/4885SMN1; SMN2 1338/4885LMNA 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.